FASE
Número Europeu 2020-001908-42
V937-013
A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors
Detalhes
Destaques